Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial (NCT03496883)
Recombinant Factor VIIa (rFVIIa) for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial
🩺 Plain-English Summary (8th-Grade Level)
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy.
Who can join: Review the eligibility criteria below.
Location: University of Alabama Hospital — Birmingham, Alabama
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (88 Sites)
Showing the first 25 of 88 sites.
- University of Alabama Hospital — Birmingham, Alabama
- St. Joseph's Hospital and Medical Center — Phoenix, Arizona
- Kaiser Permanente Baldwin Park Medical Center — Baldwin Park, California
- Mills Peninsula Medical Center — Burlingame, California
- Kaiser Permanente Downey Medical Center — Downey, California
- Kaiser Permanente Fontana Medical Center — Fontana, California
- Kaiser Permanente South Bay Medical Center — Harbor City, California
- UCSD Health La Jolla — La Jolla, California
- Kaiser Permanente Los Angeles Medical Center — Los Angeles, California
- Kaiser Permanente West Los Angeles Medical Center — Los Angeles, California
- Ronald Reagan UCLA Medical Center — Los Angeles, California
- UC Irvine Medical Center, — Orange, California
- Kaiser Permanente Riverside Medical Center — Riverside, California
- UC Davis Medical Center — Sacramento, California
- UCSD Medical Center - Hillcrest Hospital — San Diego, California
- San Francisco General Hospital — San Francisco, California
- UF Health Shands Hospital — Gainesville, Florida
- Mayo Clinic — Jacksonville, Florida
- Grady Memorial Hospital — Atlanta, Georgia
- WellStar Kennestone Hospital — Marietta, Georgia
- The Queen's Medical Center — Honolulu, Hawaii
- Northwestern Memorial Hospital — Chicago, Illinois
- University of Chicago Medical Center — Chicago, Illinois
- Central DuPage Hospital — Winfield, Illinois
- Massachusetts General Hospital — Boston, Massachusetts
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Intracerebral Hemorrhage
- ROSE-Longitudinal Assessment With Neuroimaging — Chicago, Illinois
- Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage and Ischemic Stroke — New Haven, Connecticut
- Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH) — Birmingham, Alabama
- Synergistic Minimally Invasive Surgery and Deferoxamine in ICH — Chicago, Illinois
- Auricular VNS Following Intracerebral Hemorrhage — St Louis, Missouri
Explore by condition: All Intracerebral Hemorrhage clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.